In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022.
about
Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignanciesDevelopment of inhibitors for protein tyrosine kinases.A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazolineSynthesis and evaluation of radioiodinated phenoxyquinazoline and benzylaminoquinazoline derivatives as new EGF receptor tyrosine kinase imaging ligands for tumor diagnosis using SPECT.Evaluation of radioiodinated quinazoline derivative as a new ligand for EGF receptor tyrosine kinase activity using SPECT.Strategies for improving the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo.
P2860
In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
In vivo pharmacology and anti- ...... sine kinase inhibitor RG13022.
@ast
In vivo pharmacology and anti- ...... sine kinase inhibitor RG13022.
@en
type
label
In vivo pharmacology and anti- ...... sine kinase inhibitor RG13022.
@ast
In vivo pharmacology and anti- ...... sine kinase inhibitor RG13022.
@en
prefLabel
In vivo pharmacology and anti- ...... sine kinase inhibitor RG13022.
@ast
In vivo pharmacology and anti- ...... sine kinase inhibitor RG13022.
@en
P2093
P2860
P356
P1476
In vivo pharmacology and anti- ...... sine kinase inhibitor RG13022.
@en
P2093
Brunton VG
P2860
P2888
P304
P356
10.1038/BJC.1996.620
P407
P577
1996-12-01T00:00:00Z